Dimerix Limited provided an update on the collaboration with the REMAP-CAP study into pneumonia in hospitalised patients with COVID-19. Dimerix has completed studies to confirm nasogastric delivery (delivery via feeding tube) of a DMX-200 formulation is acceptable and appropriate for patients in ICU unable to swallow a capsule. DMX-200 finished product to support the study is available and ready for recruitment throughout Europe, where cases of COVID-19 continue to climb and where contagious new variants account for the majority of new cases. Dimerix has now contracted with REMAP-CAP European clinical sites, including the UK, through the University Medical Center Utrecht (UMCU) in Utrecht, The Netherlands. The overarching REMAP-CAP study, incorporating DMX-200, is funded by the European Union through the H2020 Project called "Rapid European COVID-19 Emergency Research response," which uses the acronym "RECOVER".